Global investment meets Odense innovation – Evosep enters a new era in clinical proteomics
With Nordic Capital as majority shareholder, Evosep strengthens its global position – and Odense’s role as a rising life science city.
The recent acquisition of Evosep by Nordic Capital marks the biggest direct life science exit in EIFO history. It’s a clear signal that Denmark is not just participating in the global health innovation race – we’re building companies that can lead it.
From Local Startup to Global Player
Evosep’s journey from a local startup to a globally recognised player in clinical proteomics is rooted in Odense’s growing life science environment. This isn’t just a win for the company, but a win for the city, for Denmark, and for the strategic vision that connects research, business, and public investment.
“Evosep’s growth and the international investment are strong proof that Odense is establishing itself as a key life science city. Nordic Capital’s entry into the ownership group gives the company an even stronger foundation to realise its high ambitions. Evosep is a major strength in our life science environment, and we are looking forward to following the company’s continued journey. Both here in Odense and internationally, as the company continues to grow”
Evosep’s Mission and Global Ambitions
Evosep, headquartered in Odense, is a pioneer in clinical proteomics, developing robust and scalable LC-MS workflows that simplify complex biological analysis. With Nordic Capital’s investment, the company is now poised to expand globally and accelerate its mission to make proteomics more accessible and impactful.
“Nordic Capital has great expertise across biopharma, medtech and diagnostics, and we are thrilled to have them onboard as Evosep is moving into the next growth phase. Together, we aim to redefine how proteomics drives efficiency, quality, and insight across healthcare and life sciences. Evosep’s mission remains set in stone, and customers can expect us to continue pushing forward the standardization of LCMS-based proteomics with impactful products and solutions.”
International Collaboration and Investment
The partnership is a strong endorsement of the innovation coming out of Odense – and a clear signal that the city’s life science strategy is working. With a focus on international collaboration, talent attraction, and cross-sector innovation, Odense is becoming a natural home for companies like Evosep that are shaping the future of healthcare.
“We are very impressed by Evosep’s highly innovative and differentiated technologies to enable and enhance proteomics analysis. The company enjoys a strong and loyal backing in both academia and biopharma. Nordic Capital intends to leverage its significant expertise in diagnostics and life science tools to support Morten and his team in further expanding the company’s reach and product offering,”
Evosep’s exit is not just a milestone for one company – it’s a signal of what’s possible when innovation, investment, and local ambition align. Odense is ready to take its place among Europe’s leading life science cities – and this is just the beginning.
To learn more about Evosep’s mission and technology, visit https://www.evosep.com
Further information
Lone Krogsbøll
Investment Manager - Life Science
I help foreign companies in the biotech and life science industry to establish in Odense and connect them to relevant business partners and opportunities here. My background is in health tech, but I’ve focused on broader life science sectors since 2018.
+45 5177 7344
loak@odense.dk
Connect
Pernille Elena Stage
Investment Manager – Life Science
I work to attract and support international life science companies exploring Odense as a place to grow. With a background in biotech and experience in business development, branding, and communication, I help companies connect with local partners, research environments, and the opportunities that make Odense an emerging hub for life science innovation.
If you’re curious about what Odense can offer your company or want to explore potential collaborations, I’d be happy to start the conversation